Skip to main content
Premium Trial:

Request an Annual Quote

Micronoma, University of New South Wales to Develop Liver Cancer Dx Using $4M Grant

NEW YORK – Microbial cancer detection firm Micronoma said Tuesday that it is collaborating with the University of New South Wales, Sydney under a $4 million grant from the Australian government to apply artificial intelligence technology toward developing microbial biomarkers for the early detection of liver cancer.

Amany Zekry and Emad El-Omar, both professors at UNSW Medicine & Health, are leading the effort alongside co-principal investigator and Micronoma CSO Eddie Adams.

The group will use Micronoma's AI-driven microbial biomarker technology to detect, validate, and translate blood-borne microbial-derived biomarkers for the early detection of HCC — something the company has already been working on internally.

Micronoma CEO Sandrine Miller-Montgomery said in a statement that interest in the link between circulating microbiome signatures and cancer early detection has been growing since the firm's proof-of-concept publication in Nature last year.

"Developing a method to enable the identification of robust microbial plasma biomarker signatures of HCC is in our product pipeline, and this collaboration enables us to fast-track product development," she added.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.